BlueCross BlueShield
Federal Employee Program
Blue Cross Blue Shield Association
750 9th St NW, Suite 900
Washington, D.C. 20001
1-800-624-5060
Fax 1-877-378-4727

5.90.077

Section:	Prescription Drugs	**Effective Date:**	January 1, 2026
Subsection:	Topical Products	**Original Policy Date:**	June 20, 2025
Subject:	Tryptyr	**Page:**	1 of 5

Last Review Date: December 12, 2025

Tryptyr

Description

Tryptyr (acoltremon ophthalmic solution)

Background
Tryptyr (acoltremon) ophthalmic solution is a transient receptor potential melastatin 8 (TRPM8) thermoreceptor agonist used to treat signs and symptoms of dry eye disease (DED). TRPM8 thermoreceptor stimulation has been shown to activate trigeminal nerve signaling leading to increased basal tear production. The exact mechanism of action is unknown. Dry eye disease includes a group of conditions in which the eye does not produce an adequate volume of tears or when the tears are not of the correct consistency (1-2).

Regulatory Status
FDA-approved indication: Tryptyr is a TRPM8 thermoreceptor agonist indicated for treatment of the signs and symptoms of dry eye disease (1).

To avoid the potential for eye injury and contamination, do not touch the vial tip to the eye or other surfaces (1).

The safety and effectiveness of Tryptyr in pediatric patients less than 18 years of age have not been established (1).

Related policies
Cyclosporine Ophthalmics, Eysuvis, Miebo, Tyrvaya, Xiidra

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Tryptyr may be considered **medically necessary** if the conditions indicated below are met.

Tryptyr may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

1. Chronic dry eye
    a. Patient has been evaluated by an optometrist, ophthalmologist, or a physician specializing in the treatment of the patient's condition
    b. Inadequate treatment response, intolerance, or contraindication to **ONE** product from **EACH** of the following categories of dry eye treatment:
        i. Cellulose or polyol containing artificial tears (e.g., active ingredients such as: hydroxyethyl cellulose, methylcellulose, Dextran 70, Glycerin, povidone, etc.)
        ii. Lipid-containing artificial tears (e.g., active ingredients such as: mineral oil, castor oil, flaxseed oil, etc.)
        iii. Legend ophthalmic for the treatment of dry eyes (see Appendix 1)
    c. **NO** dual therapy with another legend ophthalmic for the treatment of dry eyes (see Appendix 1)

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

1. Chronic dry eye
   a. Patient has had an improvement in symptoms
   b. **NO** dual therapy with another legend ophthalmic for the treatment of dry eyes (see Appendix 1)

Policy Guidelines

Pre - PA Allowance
None

Prior - Approval Limits

Quantity 180 single-dose vials (3 cartons) every 90 days

Duration 12 months

Prior – Approval *Renewal* Limits
Same as above

Rationale

Summary

Tryptyr (acoltremon) ophthalmic solution is used to treat dry eye disease (DED). Dry eye disease includes a group of conditions in which the eye does not produce an adequate volume of tears or when the tears are not of the correct consistency. The exact mechanism of action is unknown. The safety and effectiveness of Tryptyr in pediatric patients less than 18 years of age have not been established (1-2).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Tryptyr while maintaining optimal therapeutic outcomes.

References

1. Tryptyr [package insert]. Fort Worth, TX: Alcon Laboratories, Inc.; May 2025.
2. Dry Eyes Syndrome Preferred Practice Pattern. American Academy of Ophthalmology. September 2018.

Policy History

Date	Action

June 2025	Addition to PA
December 2025	Annual review

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on December 12, 2025 and is effective on January 1, 2026.

Appendix 1 - List of Legend Ophthalmic Medications for Dry Eye

Generic Name	Brand Name
acoltremon	Tryptyr
cyclosporine	Cequa
cyclosporine	Restasis
cyclosporine	Vevye
lifitegrast	Xiidra
loteprednol	Eysuvis
perfluorohexyloctane	Miebo
varenicline	Tyrvaya

*Verkazia is not approved for dry eye